Articles

Cardinal Health announced plans to acquire Johnson & Johnson’s Cordis business, a leading global manufacturer of cardiology and endovascular devices, for $1.94 billion in cash. 

Daiichi Sankyo and the Heart Rhythm Society announced results from a global survey, which polled cardiologists from around the world and revealed that a majority (58 percent) agree there is no...

There have been several recent advancements in implantable cardioverter defibrillator (ICD) technology to extend battery life, improvements in patient monitoring to avoid needless shocks, the...

Medtronic, Reveal Linq ICM, atrial fibrillation, AF, study, remote monitoring

Medtronic announced the results of a new "real-world" study of patients who have had a cryptogenic stroke, in which the Reveal Linq Insertable Cardiac Monitor (ICM) detected atrial fibrillation (...

iRhythm, ZIO Service, arrhythmia detection, wearable, Holter monitors

iRhythm Technologies Inc. announced the study, “Cost Analysis and Clinical Outcomes of Ambulatory Care Monitoring in Medicare Patients,” was published in the Journal of Health...

EP lab, Implantable Cardioverter Defibrillators, Heart Failure

Boston Scientific Corporation announced the launch and first U.S. implant of its line of Extended Longevity (EL) implantable cardioverter defibrillators (ICD), including Dynagen EL and Inogen EL...

ECRI Institute has released an updated comparison on cardiac resuscitators used during cardiopulmonary resuscitation (CPR).

absorb, bioresorbable stents

DAIC readers chose the following stories as the most popular content in 2014, based on website analytics. The list is broken into the top 20 most popular news items from 2014 and a list of the top...

Medtronic, Attain Performa, quadripolar leads

Medtronic Inc. announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of two additional Attain Performa left ventricular (LV) quadripolar leads. Both devices can be...

AHA, warfarin, antiplatelet therapy, atrial fibrillation, anti-clotting, EP lab

Long-term overtreatment with the anti-clotting drug warfarin combined with antiplatelet therapy to prevent stroke may raise the risk of dementia in people with atrial fibrillation.